{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:02:38Z","timestamp":1773288158432,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":25,"publisher":"Springer US","isbn-type":[{"value":"9781071620090","type":"print"},{"value":"9781071620106","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different <jats:italic>DMD<\/jats:italic> exons. Preclinical screening of the new oligonucleotide sequences is routinely performed using patient-derived cell cultures, and evaluation of their efficacy may be performed at RNA and\/or protein level. While several methods to assess exon skipping and dystrophin expression in cell culture have been developed, the choice of methodology often depends on the availability of specific research equipment.<\/jats:p><jats:p>In this chapter, we describe and indicate the relevant bibliography of all the methods that may be used in this evaluation and describe in detail the protocols routinely followed at our institution, one to evaluate the efficacy of skipping at RNA level (nested PCR) and the other the restoration of protein expression (myoblot), which provide good results using equipment largely available to most research laboratories.<\/jats:p>","DOI":"10.1007\/978-1-0716-2010-6_14","type":"book-chapter","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T11:11:35Z","timestamp":1645787495000},"page":"217-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy"],"prefix":"10.1007","author":[{"given":"Andrea","family":"L\u00f3pez-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Soblechero-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-3255","authenticated-orcid":false,"given":"Virginia","family":"Arechavala-Gomeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"14_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR, DMD Care Consideration Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17:251. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3","journal-title":"Lancet Neurol"},{"issue":"pt 12","key":"14_CR2","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/brain\/awr291","volume":"134","author":"K Anthony","year":"2011","unstructured":"Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, Armaroli A, Guglieri M, Straathof CS, Verschuuren JJ, Aartsma-Rus A, Helderman-van den Enden P, Bushby K, Straub V, Sewry C, Ferlini A, Ricci E, Morgan JE, Muntoni F (2011) Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 134(pt 12):3547\u20133559. https:\/\/doi.org\/10.1093\/brain\/awr291","journal-title":"Brain"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TACG.S71506","volume":"7","author":"V Arechavala-Gomeza","year":"2014","unstructured":"Arechavala-Gomeza V, Khoo B, Aartsma-Rus A (2014) Splicing modulation therapy in the treatment of genetic diseases. Appl Clin Genet 7:245\u2013252. https:\/\/doi.org\/10.2147\/TACG.S71506","journal-title":"Appl Clin Genet"},{"key":"14_CR4","doi-asserted-by":"publisher","unstructured":"Echevarria L, Aupy P, Goyenvalle A (2018) Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. https:\/\/doi.org\/10.1093\/hmg\/ddy171","DOI":"10.1093\/hmg\/ddy171"},{"issue":"3","key":"14_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293\u2013299. https:\/\/doi.org\/10.1002\/humu.20918","journal-title":"Hum Mutat"},{"key":"14_CR6","unstructured":"US Food and Drug Administration (FDA) (2016) FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm. Accessed 24 Jan 2017"},{"key":"14_CR7","doi-asserted-by":"crossref","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, Charleston JS, Sardone V, Domingos J, Dickson G, Straub V, Guglieri M, Mercuri E, Servais L, Muntoni F (2020) SKIP-NMD Study Group. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 94(21):e2270\u2013e2282. https:\/\/doi.org\/10.1212\/WNL.0000000000009233. Epub 2020 Mar 5. PMID: 32139505; PMCID: PMC7357297","DOI":"10.1212\/WNL.0000000000009233"},{"issue":"9791","key":"14_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","volume":"378","author":"S Cirak","year":"2011","unstructured":"Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378(9791):595\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(11)60756-3","journal-title":"Lancet"},{"issue":"10","key":"14_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Viltolarsen: first approval. Drugs 80(10):1027\u20131031. https:\/\/doi.org\/10.1007\/s40265-020-01339-3","journal-title":"Drugs"},{"key":"14_CR10","unstructured":"US Food and Frug Administration (FDA) (2021) FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-1-61737-982-6_10","volume":"709","author":"LJ Popplewell","year":"2011","unstructured":"Popplewell LJ, Graham IR, Malerba A, Dickson G (2011) Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle. Methods Mol Biol 709:153\u2013178. https:\/\/doi.org\/10.1007\/978-1-61737-982-6_10","journal-title":"Methods Mol Biol"},{"issue":"2","key":"14_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nmd.2009.10.013","volume":"20","author":"LJ Popplewell","year":"2010","unstructured":"Popplewell LJ, Adkin C, Arechavala-Gomeza V, Aartsma-Rus A, de Winter CL, Wilton SD, Morgan JE, Muntoni F, Graham IR, Dickson G (2010) Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: implications for future clinical trials. Neuromuscul Disord 20(2):102\u2013110. https:\/\/doi.org\/10.1016\/j.nmd.2009.10.013","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"14_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jpm7040013","volume":"7","author":"Q Nguyen","year":"2017","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med 7(4):13. https:\/\/doi.org\/10.3390\/jpm7040013","journal-title":"J Pers Med"},{"issue":"4","key":"14_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/oli.2005.15.284","volume":"15","author":"A Aartsma-Rus","year":"2005","unstructured":"Aartsma-Rus A, De Winter CL, Janson AA, Kaman WE, Van Ommen GJ, Den Dunnen JT, Van Deutekom JC (2005) Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15(4):284\u2013297. https:\/\/doi.org\/10.1089\/oli.2005.15.284","journal-title":"Oligonucleotides"},{"issue":"9","key":"14_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/hum.2006.061","volume":"18","author":"V Arechavala-Gomeza","year":"2007","unstructured":"Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, Morgan JE, van Deutekom JC, Wilton SD, Dickson G, Muntoni F (2007) Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18(9):798\u2013810. https:\/\/doi.org\/10.1089\/hum.2006.061","journal-title":"Hum Gene Ther"},{"issue":"1","key":"14_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1086\/381039","volume":"74","author":"A Aartsma-Rus","year":"2004","unstructured":"Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74(1):83\u201392. https:\/\/doi.org\/10.1086\/381039","journal-title":"Am J Hum Genet"},{"issue":"10","key":"14_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204485","volume":"13","author":"M Hiller","year":"2018","unstructured":"Hiller M, Falzarano MS, Garcia-Jimenez I, Sardone V, Verheul RC, Popplewell L, Anthony K, Ruiz-Del-Yerro E, Osman H, Goeman JJ, Mamchaoui K, Dickson G, Ferlini A, Muntoni F, Aartsma-Rus A, Arechavala-Gomeza V, Datson NA, Spitali P (2018) A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures. PLoS One 13(10):e0204485. https:\/\/doi.org\/10.1371\/journal.pone.0204485","journal-title":"PLoS One"},{"issue":"5","key":"14_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/hgtb.2012.117","volume":"23","author":"K Anthony","year":"2012","unstructured":"Anthony K, Feng L, Arechavala-Gomeza V, Guglieri M, Straub V, Bushby K, Cirak S, Morgan J, Muntoni F (2012) Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen. Hum Gene Ther Methods 23(5):336\u2013345. https:\/\/doi.org\/10.1089\/hgtb.2012.117","journal-title":"Hum Gene Ther Methods"},{"issue":"4","key":"14_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195850","volume":"13","author":"C Beekman","year":"2018","unstructured":"Beekman C, Janson AA, Baghat A, van Deutekom JC, Datson NA (2018) Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy. PLoS One 13(4):e0195850. https:\/\/doi.org\/10.1371\/journal.pone.0195850","journal-title":"PLoS One"},{"issue":"22","key":"14_CR20","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1212\/WNL.0000000000001025","volume":"83","author":"K Anthony","year":"2014","unstructured":"Anthony K, Arechavala-Gomeza V, Taylor LE, Vulin A, Kaminoh Y, Torelli S, Feng L, Janghra N, Bonne G, Beuvin M, Barresi R, Henderson M, Laval S, Lourbakos A, Campion G, Straub V, Voit T, Sewry CA, Morgan JE, Flanigan KM, Muntoni F (2014) Dystrophin quantification: biological and translational research implications. Neurology 83(22):2062\u20132069. https:\/\/doi.org\/10.1212\/WNL.0000000000001025","journal-title":"Neurology"},{"issue":"5","key":"14_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/nan.12448","volume":"44","author":"E Ruiz-Del-Yerro","year":"2018","unstructured":"Ruiz-Del-Yerro E, Garcia-Jimenez I, Mamchaoui K, Arechavala-Gomeza V (2018) Myoblots: dystrophin quantification by in-cell western assay for a streamlined development of Duchenne muscular dystrophy (DMD) treatments. Neuropathol Appl Neurobiol 44(5):463\u2013473. https:\/\/doi.org\/10.1111\/nan.12448","journal-title":"Neuropathol Appl Neurobiol"},{"key":"14_CR22","doi-asserted-by":"publisher","unstructured":"Aartsma-Rus A, Morgan J, Lonkar P, Neubert H, Owens J, Binks M, Montolio M, Phadke R, Datson N, Van Deutekom J, Morris GE, Rao VA, Hoffman EP, Muntoni F, Arechavala-Gomeza V, workshop p (2019) Report of a TREAT-NMD\/world Duchenne organisation meeting on dystrophin quantification methodology. J Neuromuscular Dis 6 (1):147\u2013159. doi:https:\/\/doi.org\/10.3233\/JND-180357","DOI":"10.3233\/JND-180357"},{"issue":"9","key":"14_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162467","volume":"11","author":"RC Verheul","year":"2016","unstructured":"Verheul RC, van Deutekom JC, Datson NA (2016) Digital droplet PCR for the absolute quantification of exon skipping induced by antisense oligonucleotides in (pre-)clinical development for Duchenne muscular dystrophy. PLoS One 11(9):e0162467. https:\/\/doi.org\/10.1371\/journal.pone.0162467","journal-title":"PLoS One"},{"issue":"8","key":"14_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41582-018-0033-8","volume":"14","author":"A Aartsma-Rus","year":"2018","unstructured":"Aartsma-Rus A, Arechavala-Gomeza V (2018) Why dystrophin quantification is key in the eteplirsen saga. Nat Rev Neurol 14(8):454\u2013456. https:\/\/doi.org\/10.1038\/s41582-018-0033-8","journal-title":"Nat Rev Neurol"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A, Kandalla PK, Marie S, Di Santo J, St Guily JL, Muntoni F, Kim J, Philippi S, Spuler S, Levy N, Blumen SC, Voit T, Wright WE, Aamiri A, Butler-Browne G, Mouly V (2011) Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle 1:34. https:\/\/doi.org\/10.1186\/2044-5040-1-34","journal-title":"Skelet Muscle"}],"container-title":["Methods in Molecular Biology","Antisense RNA Design, Delivery, and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2010-6_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:32:40Z","timestamp":1650587560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2010-6_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071620090","9781071620106"],"references-count":25,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2010-6_14","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"25 February 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}